- Home
- AYTU vs SONN Comparison
AYTU vs SONN Comparison
Compare AYTU & SONN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AYTU
- SONN
- Stock Information
- Founded
- AYTU N/A
- SONN N/A
- Country
- AYTU United States
- SONN United States
- Employees
- AYTU N/A
- SONN N/A
- Industry
- AYTU Biotechnology: Pharmaceutical Preparations
- SONN Biotechnology: Pharmaceutical Preparations
- Sector
- AYTU Health Care
- SONN Health Care
- Exchange
- AYTU Nasdaq
- SONN Nasdaq
- Market Cap
- AYTU 19.7M
- SONN 21.4M
- IPO Year
- AYTU N/A
- SONN N/A
- Fundamental
- Price
- AYTU $2.37
- SONN $7.58
- Analyst Decision
- AYTU Strong Buy
- SONN Strong Buy
- Analyst Count
- AYTU 2
- SONN 1
- Target Price
- AYTU $10.00
- SONN $20.00
- AVG Volume (30 Days)
- AYTU 100.5K
- SONN 1.4M
- Earning Date
- AYTU 11-12-2025
- SONN 08-13-2025
- Dividend Yield
- AYTU N/A
- SONN N/A
- EPS Growth
- AYTU N/A
- SONN N/A
- EPS
- AYTU N/A
- SONN N/A
- Revenue
- AYTU $81,659,000.00
- SONN $1,000,000.00
- Revenue This Year
- AYTU N/A
- SONN $5,376.22
- Revenue Next Year
- AYTU $2.00
- SONN N/A
- P/E Ratio
- AYTU N/A
- SONN N/A
- Revenue Growth
- AYTU 0.41
- SONN 1689.52
- 52 Week Low
- AYTU $0.95
- SONN $1.08
- 52 Week High
- AYTU $2.85
- SONN $19.30
- Technical
- Relative Strength Index (RSI)
- AYTU 55.75
- SONN 78.67
- Support Level
- AYTU $2.21
- SONN $2.71
- Resistance Level
- AYTU $2.58
- SONN $7.90
- Average True Range (ATR)
- AYTU 0.13
- SONN 0.90
- MACD
- AYTU 0.01
- SONN 0.48
- Stochastic Oscillator
- AYTU 48.78
- SONN 93.83
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.